Epigenetic Modulator Screening
Epigenetic modifications have been shown to regulate a wide range of physiological and pathological processes. Epigenetic alterations can also be used as the biomarkers and therapeutic targets in many diseases leading to led drug and biotechnology companies to actively search for intervention agents of epigenetic alterations.
Cambridge Bioscience offers access to a epigentic enzyme inhibitor screening service from Epigentek. This screening system provides a platform that not only allows the testing of inhibitors against total enzymatic activity but also allows the screening of inhibitors specific to individual HDACs & Dnmts.
Features of the Epigentic Enzyme Inhibitor Screening Service
This service enables the following:
• Enhancement of drug discovery & development without the burden of increased staff & equipment
• Better drug candidates to be chosen for further development
• Determination of the specificity of lead candidates against a wide range of epigenetic targets
• Validation of lead candidates in a rapid, reliable & high throughput assay format
Epigenase™ Epigenetic Enzyme Inhibitor Screening System
Inhibitors that target enzymes such as HDACs and Dnmts have proven effective as novel cancer therapeutic agents. The enzymes included in the Epigenase™ screening system are with important biological and therapeutic relevance. With a proprietary technology, the Epigenase™ screening system provides a platform that not only allows the testing of inhibitors against total enzymatic activity but also allows the screening of inhibitors specific to individual HDACs and Dnmts.
Request A No Obligation Quote
To discuss a epigenetic enzyme inhibitor screening project, please contact our experienced team by Clicking Here